CureVac (NASDAQ:CVAC) | Finanzwire

Basculer en Français

10590	Companies
224541	Keywords
153292	Articles
118775	Press releases

Home
Companies
CureVac

PRESS RELEASE

published on 11/04/2024 at 13:03, 1 year 7 months ago

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer
CureVac appoints Axel Sven Malkomes as CFO, bringing 30 years of industry experience. His role will drive strategic initiatives, financial foundation, and shareholder value

Biopharmaceutical Company CFO MRNA Technology CureVac Axel Sven Malkomes
PRESS RELEASE

published on 11/04/2024 at 13:00, 1 year 7 months ago

CureVac to Present at the 12th International mRNA Health Conference
CureVac to present new data at the 12th International mRNA Health Conference, showcasing developments in mRNA cancer vaccine and lipid nanoparticle delivery technology

Innovation Biopharmaceutical CureVac MRNA Platform MRNA Health Conference
BRIEF

published on 10/28/2024 at 13:05, 1 year 7 months ago

CureVac to Present New Findings at SITC Annual Meeting

Clinical Trials MRNA Technology Cancer Vaccine CureVac SITC Meeting
PRESS RELEASE

published on 10/28/2024 at 13:00, 1 year 7 months ago

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
CureVac to present at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, sharing immunogenicity data on mRNA-based cancer vaccine CVGBM. Conference details and contact info provided

CureVac MRNA Poster Presentation Immunogenicity Society For Immunotherapy Of Cancer
BRIEF

published on 09/13/2024 at 14:02, 1 year 9 months ago

CureVac's CVGBM Cancer Vaccine Shows Promising Results in Phase 1 Glioblastoma Study

CureVac Glioblastoma CVGBM Phase 1 Study T-cell Responses
PRESS RELEASE

published on 09/13/2024 at 13:57, 1 year 9 months ago

CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
CureVac's CVGBM Cancer Vaccine induces promising immune responses in Phase 1 Study in Glioblastoma presented at ESMO 2024 Congress. Results show de novo T-cell activity & acceptable safety profile up to 100 µg dose

Cancer Vaccine CureVac CVGBM Phase 1 Study Immune Responses
BRIEF

published on 09/12/2024 at 13:02, 1 year 9 months ago

CureVac and GSK Report Positive Phase 2 Data for Influenza mRNA Vaccine

MRNA Technology Influenza Vaccine Phase 2 Results GSK Partnership CureVac Milestone
PRESS RELEASE

published on 09/12/2024 at 12:57, 1 year 9 months ago

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
CureVac Partner GSK reports positive Phase 2 results for seasonal influenza mRNA vaccine program. Data show immune responses to A and B strains with acceptable safety profile

GSK CureVac Phase 2 MRNA Vaccine Seasonal Influenza
BRIEF

published on 09/09/2024 at 13:05, 1 year 9 months ago

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

Clinical Data CureVac MRNA Vaccine Glioblastoma ESMO Congress
PRESS RELEASE

published on 09/09/2024 at 13:00, 1 year 9 months ago

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
CureVac to present first CVGBM Glioblastoma cancer vaccine clinical data at ESMO 2024 Congress. First-in-human study results to be shared, highlighting mRNA technology's potential for cancer vaccines

MRNA Technology CureVac Glioblastoma CVGBM ESMO 2024 Congress

Accesswire

Published on 06/17/2026 at 16:55, 3 hours 10 minutes ago

Snipp Interactive Named a Representative Vendor in the Gartner(R) 2026 Market Guide for Loyalty Program Vendors
Published on 06/17/2026 at 16:45, 3 hours 20 minutes ago

Nymox's Nymozarfex(TM) Newly Available for Prostate Treatments for Medical Tourists in Collaboration with the Global Alliance of Regenerative Medicine on Roatan Island in the Caribbean
Published on 06/17/2026 at 14:30, 5 hours 35 minutes ago

Solitario Advances 2026 Ponderosa Drilling Program
Published on 06/17/2026 at 14:00, 6 hours 5 minutes ago

CHAR Tech Reminds Shareholders of June 18 Investor Update Call
Published on 06/17/2026 at 14:00, 6 hours 5 minutes ago

Trifecta Gold Increases Private Placement

View all ACCESSWIRE

EQS Group

Published on 06/17/2026 at 19:10, 55 minutes ago

Africa Finance Corporation and Leading Italian Institutions Sign Strategic Cooperation Agreements at AFC-Italy Forum to Mobilise Capital and Accelerate Industrial Development Across Africa
Published on 06/17/2026 at 18:40, 1 hour 25 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 06/17/2026 at 18:36, 1 hour 28 minutes ago

BILENDI: Bilendi announces that Euroland Corporate has initiated coverage of its shares
Published on 06/17/2026 at 18:23, 1 hour 41 minutes ago

EQS-Adhoc: Ludwig Beck am Rathauseck-Textilhaus Feldmeier AG: Conclusion of a delisting agreement with Bayerische Gewerbebau AG
Published on 06/17/2026 at 18:05, 1 hour 59 minutes ago

WACACO LAUNCHES PRESTINA, A PATENTED MANUAL COFFEE BREWER THAT TURNS THE CUP INTO THE PRESS

Les Echos

Published on 06/17/2026 at 17:40, 2 hours 25 minutes ago

Report on share repurchases from 10 to 16 June 2026
Published on 06/17/2026 at 08:45, 11 hours 20 minutes ago

Air Liquide is awarded its largest-ever contract in Spain to care for 90,000 patients living with respiratory conditions at home
Published on 06/16/2026 at 11:44, 1 day 8 hours ago

Guillemot Corporation S.A. | Weekly report share buyback from June 8 to June 12 2026
Published on 06/15/2026 at 23:00, 1 day 21 hours ago

BIOPHYTIS ANNOUNCES THE TEMPORARY SUSPENSION OF THE TRADING OF ITS SHARES
Published on 06/15/2026 at 18:57, 2 days 1 hour ago

Reporting on share buyback transactions carried out between June 8 and June 11, 2026

View all LES ECHOS COMFI WIRE